Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Clinical Investigation

• Publication date

  2008-01-02

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1172/JCI32103PMID 18060041PMCID PMC2104476
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The IL-15/IL-15Rα on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells

  2007cited by this paper
• Adoptive immunotherapy for cancer: building on success

  2006cited by this paper
• Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes

  2006cited by this paper
• Chromatin structure and gene regulation in T cell development and function.

  2006cited by this paper
• The descent of memory T-cell subsets

  2006cited by this paper
• Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation.

  2006cited by this paper
• Highly Protective In Vivo Function of Cytomegalovirus IE1 Epitope-Specific Memory CD8 T Cells Purified by T-Cell Receptor-Based Cell Sorting

  2005cited by this paper
• Telomere Length of Transferred Lymphocytes Correlates with In Vivo Persistence and Tumor Regression in Melanoma Patients Receiving Cell Transfer Therapy1

  2005cited by this paper
• Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.

  2005cited by this paper
• Initial T cell frequency dictates memory CD8+ T cell lineage commitment

  2005cited by this paper
• Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

  2005cited by this paper
• Molecular Signatures Distinguish Human Central Memory from Effector Memory CD8 T Cell Subsets1

  2005cited by this paper
• Modulation of Hematopoietic Stem Cell Homing and Engraftment by CD26

  2004cited by this paper
• The role of programming in memory T-cell development.

  2004cited by this paper
• Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease

  2004cited by this paper
• Central memory and effector memory T cell subsets: function, generation, and maintenance.

  2004cited by this paper
• Cancer Immunotherapy: A Treatment for the Masses

  2004cited by this paper
• Molecules and mechanisms of the graft-versus-leukaemia effect

  2004cited by this paper
• Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model.

  2004cited by this paper
• Retroviral Vectors for High-Level Transgene Expression in T Lymphocytes

  2003cited by this paper
• Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15

  2003cited by this paper
• Lineage relationship and protective immunity of memory CD8 T cell subsets

  2003cited by this paper
• Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells

  2003cited by this paper
• Telomere length measurements in leukocyte subsets by automated multicolor flow‐FISH

  2003cited by this paper
• Impact of simian immunodeficiency virus (SIV) infection on lymphocyte numbers and T-cell turnover in different organs of rhesus monkeys.

  2003cited by this paper
• Targeting tumours with genetically enhanced T lymphocytes

  2003cited by this paper
• Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

  2002cited by this paper
• Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells

  2002cited by this paper
• Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections

  2002cited by this paper
• Development and Homeostasis of T Cell Memory in Rhesus Macaque1

  2002influential reference
• Cutting Edge: Requirement for IL-15 in the Generation of Primary and Memory Antigen-Specific CD8 T Cells1

  2002cited by this paper
• Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

  2002cited by this paper
• Interleukin 15 Is Required for Proliferative Renewal of Virus-specific Memory CD8 T Cells

  2002cited by this paper
• Arrested Differentiation, the Self-Renewing Memory Lymphocyte, and Vaccination

  2001cited by this paper
• Immunotherapy through TCR gene transfer

  2001cited by this paper
• Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer

  2001cited by this paper
• Nonmyeloablative Immunosuppressive Regimen Prolongs In Vivo Persistence of Gene-Modified Autologous T Cells in a Nonhuman Primate Model

  2001cited by this paper
• Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma

  2001cited by this paper
• IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice.

  2000cited by this paper
• Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4.

  1999cited by this paper
• Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

  1999cited by this paper
• Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.

  1998cited by this paper
• Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry

  1998cited by this paper
• Lymphocyte Homing and Homeostasis

  1996cited by this paper
• T–cell mediated rejection of gene–modified HIV–specific cytotoxic T lymphocytes in HIV–infected patients

  1996cited by this paper
• Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.

  1995cited by this paper
• A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V.

  1995cited by this paper
• Human cytomegalovirus latent infection of granulocyte-macrophage progenitors.

  1994cited by this paper
• Antigen‐presenting human T cells and antigen‐presenting B cells induce a similar cytokine profile in specific T cell clones

  1993cited by this paper
• Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones.

  1992cited by this paper
• Specificity of adoptive chemoimmunotherapy of established syngeneic tumors.

  1980cited by this paper

• Adoptive γδ T cell therapy controls cytomegalovirus infection in preclinical transplantation models.

  2026cites this paper
• IL-15 overexpression promotes memory program and anti-tumor activity of CD64 CAR T cells in a preclinical AML model

  2026cites this paper
• Bidirectionally H2O2-suppliable and antioxidant-consumable copper peroxide nanoparticles for photochemodynamic immunotherapy.

  2026cites this paper
• CAR-T cell therapies are coming after glioblastoma: An overview of early phase clinical trials and future perspectives

  2026cites this paper
• Prdm12 governs an epigenetic checkpoint linking neuroimmune cross-talk to CD8+ T cell exhaustion-suppressed antitumor immunity

  2025cites this paper
• Novel antibodies for identification, selection, and manipulation of T cells expressing Whitlow linker-containing CARs

  2025cites this paper
• Adaptive immune responses against common viruses are sustained and functional in end-of-life patients

  2025cites this paper
• Gene transfer and genome editing of T cells for cancer immunotherapy: from allogeneic HSCT to TCR gene editing.

  2025cites this paper
• Adoptive T Cell Therapy Targeting MAGE-A4

  2025cites this paper
• Peripheral immune profiling highlights a dynamic role of low-density granulocytes in myasthenia gravis.

  2025cites this paper
• Improved Antitumor Activity of Interleukin-12-Secreting Chimeric Antigen Receptor T Cells Targeting CD176 across Different Carcinomas.

  2025cites this paper
• Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma.

  2025cites this paper
• Shared donor–recipient γδ T‐cell phenotypic and repertoire features associate with cytomegalovirus reactivation after allogeneic haematopoietic stem cell transplantation

  2025cites this paper
• Mechanostimulatory Platform for Improved CAR T Cell Immunotherapy

  2025cites this paper
• Cholesterol modified defense peptide as an EMP2-siRNA delivery system for synergistic immunogene therapy against breast cancer

  2025cites this paper
• T cell receptor usage and epitope specificity amongst CD8+ and CD4+ SARS-CoV-2-specific T cells

  2025cites this paper
• A Scalable Protocol for Ex Vivo Production of CAR-Engineered Human NK Cells

  2025cites this paper
• Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma

  2025cites this paper
• Pediatric Long COVID Is Characterized by Myeloid CCR6 Suppression and Immune Dysregulation

  2025cites this paper
• LLT1 overexpression renders allogeneic-NK resistance and facilitates the generation of enhanced universal CAR-T cells

  2025cites this paper
• Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies

  2025cites this paper
• Vaccine-induced T cell receptor T cell therapy targeting a glioblastoma stemness antigen

  2025cites this paper
• Expanded and activated marrow-infiltrating lymphocytes exhibit potent antimyeloma activity against autologous multiple myeloma cells

  2025cites this paper
• Mechanisms and interventions in relapsed/refractory extranodal natural killer/T-cell lymphoma.

  2025cites this paper
• Cutaneous Immune Memory: A Double-Edged Sword in Skin Repair and Fibrosis.

  2025cites this paper
• Blockade of co-inhibitory receptor immune checkpoint protein TIM3/CD366 augments the anti-cancer activity of CAR-T therapy in solid tumors: An ovarian cancer example

  2025cites this paper
• Safety, efficacy and total cost of point-of-care manufactured anti-CD19 CAR-T cell therapy in India: VELCART trial

  2025cites this paper
• Predictors of patients with advanced pancreatic cancer undergoing conversion surgery via chemoimmunotherapy with a multifunctional Wilms’ tumor 1 (WT1) peptide cocktail-pulsed dendritic cell vaccine

  2025cites this paper
• Tumor-specific CD8+ T cells from the bone marrow resist exhaustion and exhibit increased persistence in tumor-bearing hosts as compared with tumor-infiltrating lymphocytes

  2025cites this paper
• A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence

  2025cites this paper
• A multi-kinase inhibitor screen identifies inhibitors preserving stem-cell-like chimeric antigen receptor T cells

  2025cites this paper
• CliniMACS Prodigy Manufacturing of Switchable, AND-Gate CAR T Cells

  2025cites this paper
• Engineering mRNA CAR-T Cells for Cancer Immunotherapy.

  2025cites this paper
• Efficient and Traceless Aptamer‐Based Serial Selection of Naïve and Early Memory CD8 T Cells for CAR T Cell Therapy

  2025cites this paper
• MerTK Signaling in Human Primary T cells Modulates Memory Potential and Improves Recall response.

  2024cites this paper
• Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis

  2024cites this paper
• Th9 Cells Represent a Unique Subset of CD4+ T Cells Endowed with the Ability to Eradicate Advanced Tumors.

  2024cites this paper
• Genetically modified and unmodified cellular approaches to enhance graft versus leukemia effect, without increasing graft versus host disease: the use of allogeneic cytokine-induced killer cells

  2024cites this paper
• Choice of activation protocol impacts the yield and quality of CAR T cell product, particularly with older individuals

  2024cites this paper
• Rapidly Manufactured CAR-T with Conserved Cell Stemness and Distinctive Cytokine-Secreting Profile Shows Improved Anti-Tumor Efficacy

  2024cites this paper
• Ex vivo T cell differentiation in adoptive immunotherapy manufacturing: Critical process parameters and analytical technologies.

  2024cites this paper
• Acute Myeloid Leukemia Skews Therapeutic WT1-specific CD8 TCR-T Cells Towards an NK-like Phenotype that Compromises Function and Persistence

  2024cites this paper
• Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapy

  2024cites this paper
• The Confounding Role of Graft-Versus-Host Disease in Animal Models of Cancer Immunotherapy: A Systematic Review

  2024cites this paper
• Clinical trials, challenges, and changes in TCR-based therapeutics for hematologic malignancies

  2024cites this paper
• Higher TIGIT+ γδ TCM cells may predict poor prognosis in younger adult patients with non-acute promyelocytic AML

  2024influential citation
• HA-1-targeted T cell receptor (TCR) T cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.

  2024cites this paper
• Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma

  2024cites this paper
• PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion

  2024cites this paper
• Portable platform for leukocyte extraction from blood using sheath-free microfluidic DLD.

  2024cites this paper
• Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR–T) cell immunotherapy

  2024cites this paper
• CAR-T cell manufacturing: Major process parameters and next-generation strategies

  2024cites this paper
• Tipping the balance in autoimmunity: are regulatory t cells the cause, the cure, or both?

  2024cites this paper
• High CD62L expression predicts the generation of chimeric antigen receptor T cells with potent effector functions.

  2024cites this paper
• Peripheral T Cell Subpopulations as a Potential Surrogate Biomarker during Atezolizumab plus Bevacizumab Treatment for Hepatocellular Carcinoma

  2024cites this paper
• The TOPK inhibitor HI-TOPK-032 enhances CAR T-cell therapy of hepatocellular carcinoma by upregulating memory T cells.

  2024cites this paper
• Exploring the evolution of T cell function and diversity across different stages of non-small cell lung cancer.

  2024cites this paper
• EBV T-cell immunotherapy generated by peptide selection has enhanced effector functionality compared to LCL stimulation

  2024cites this paper
• Digital twins elucidate critical role of Tscm in clinical persistence of TCR-engineered cell therapy

  2024cites this paper
• Automated manufacture of ΔNPM1 TCR-engineered T cells for AML therapy

  2024cites this paper
• Bridging treatment prior to chimeric antigen receptor T‐cell therapy in multiple myeloma

  2023cites this paper
• PD1+TIGIT+2B4+KLRG1+ cells might underlie T-cell dysfunction in patients treated with BCMA-directed CAR-T therapy.

  2023cites this paper
• Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer

  2023cites this paper
• CD276-CAR T cells and Dual-CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models

  2023cites this paper
• Implications of High Tumor Burden on Chimeric Antigen Receptor T-Cell Immunotherapy: A Review.

  2023cites this paper
• T cell memory revisited using single telomere length analysis

  2023cites this paper
• CAR T cells recognizing CD276 and Dual-CAR T cells against CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models

  2023cites this paper
• INSPIRED Symposium Part 4B: CAR T cell correlative studies-established findings and future priorities.

  2023cites this paper
• Tumor-Specific CD8+ T Cells from the Bone Marrow Resist Exhaustion and Exhibit Increased Persistence in Tumor-Bearing Hosts as Compared to Tumor Infiltrating Lymphocytes

  2023cites this paper
• Cell Granularity Reflects Immune Cell Function and Enables Selection of Lymphocytes with Superior Attributes for Immunotherapy

  2023cites this paper
• Single-cell transcriptomic profiling reveals immune cell heterogeneity in acute myeloid leukaemia peripheral blood mononuclear cells after chemotherapy

  2023cites this paper
• Memory T Cells in the Immunoprevention of Cancer: A Switch from Therapeutic to Prophylactic Approaches.

  2023cites this paper
• Construction of a prognostic signature of RFC5 immune-related genes in patients with cervical cancer

  2023cites this paper
• Immune-based therapies in diffuse large B-cell lymphoma

  2023cites this paper
• Express Delivery of Next-Generation CAR T Cells with Preserved Naive and Stemness Phenotypes for the Treatment of Aggressive Lymphomas.

  2023cites this paper
• Elderly CD8+ T cells in the focus for immunotherapeutic approaches

  2023cites this paper
• A Potential Biomarker of Dynamic Change in Peripheral CD45RA−CD27+CD127+ Central Memory T Cells for Anti-PD-1 Therapy in Patients with Esophageal Squamous Cell Carcinoma

  2023cites this paper
• Comparative Pre-Clinical Analysis of CD20-Specific CAR T Cells Encompassing 1F5-, Leu16-, and 2F2-Based Antigen-Recognition Moieties

  2023cites this paper
• Deconvolution of clinical variance in CAR-T cell pharmacology and response

  2023influential citation
• Application of CAR‐T cell technology in autoimmune diseases and human immunodeficiency virus infection treatment

  2023cites this paper
• Stepwise activities of mSWI/SNF family chromatin remodeling complexes direct T cell activation and exhaustion

  2023cites this paper
• Analysis of causes for poor persistence of CAR-T cell therapy in vivo

  2023cites this paper
• Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers

  2023cites this paper
• Tracking Peripheral Memory T Cell Subsets in Advanced Nonsmall Cell Lung Cancer Treated with Hypofractionated Radiotherapy and PD-1 Blockade

  2023cites this paper
• Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy

  2023cites this paper
• Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models

  2023cites this paper
• T cell immunotherapy for cervical cancer: challenges and opportunities

  2023cites this paper
• Role of Suprabasin in the Dedifferentiation of Follicular Epithelial Cell-Derived Thyroid Cancer and Identification of Related Immune Markers

  2022cites this paper
• Better by design: What to expect from novel CAR-engineered cell therapies?

  2022cites this paper
• Strategies for manufacturing cell therapy products aligned with patient needs.

  2022cites this paper
• Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours

  2022cites this paper
• Hypoxia-inducible lentiviral gene expression in engineered human macrophages

  2022cites this paper
• The Impact of Esophageal Oncological Surgery on Perioperative Immune Function; Implications for Adjuvant Immune Checkpoint Inhibition

  2022cites this paper
• Rapid manufacturing of non-activated potent CAR T cells

  2022cites this paper
• Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment

  2022cites this paper
• Innate and adaptive immunity in cancer

  2022cites this paper
• Delineation of T cell subsets in chronic rhinosinusitis with nasal polyps

  2022cites this paper
• Manipulating T-cell metabolism to enhance immunotherapy in solid tumor

  2022cites this paper
• Development of a cGMP-compliant process to manufacture donor-derived, CD45RA-depleted memory CD19-CAR T cells

  2022cites this paper
• AIM™ platform: A new immunotherapy approach for viral diseases

  2022cites this paper